SOURCE: Goldman Small Cap Research, Inc.

July 11, 2013 08:58 ET

With Plandai's Products, East Meets West

BALTIMORE, MD--(Marketwired - Jul 11, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that until a recent landmark study by Plandai Biotechnology, Inc. (OTCQB: PLPL) that demonstrated the greatest absorption of the key nutrients, known as catechins, found in green tea into the bloodstream, many of the studies conducted on green tea's health benefits have come from the Far East. Interestingly, while the Asian studies have been profound for their findings, they serve as an important precursor to the upcoming and game-changing Plandai extended studies.

Much like green tea was introduced by the East to the West, early studies of green tea's health benefits were largely conducted in Asia, with significant results. Some of these early human studies have even shown that drinking at least two cups of green tea daily inhibits cancer growth.

For example, a recent analysis of 22 studies that probed the correlation between high tea consumption and reduced risk for lung cancer concluded that by increasing the consumption of green tea by two cups each day may reduce the risk of developing lung cancer.

Clearly, the properties in the green tea catechins and antioxidants have a positive impact on our health. However, since there is limited bioavailability or absorption potential into the bloodstream, daily tea consumption in beverage form has had to be significant in order to receive its benefits. Conversely, Plandai has demonstrated that due to its extraction and delivery process, absorption rates of these key nutrients through its products can be many times that of typical bioavailability rates. Therefore, it is logical to assume that going forward, studies in the West will show even greater health benefits from these catechins than the studies conducted in the East. These results should then lead to increased and broader consumption of green tea and green tea extracts, led by Plandai's offerings and ingredients in many manufacturers' products across the globe.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit

Contact Information